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Recombinant human growth hormone and
insulin-like growth factor-1 do not affect
mitochondrial derived highly reactive
oxygen species production in peripheral
blood mononuclear cells under conditions
of substrate saturation in-vitro
James Keane*, Lotti Tajouri and Bon Gray
Abstract
Background: The purpose of this study was to investigate the mitochondrial effects exerted by physiological
and supra-physiological concentrations of recombinant human growth hormone (rhGH) and recombinant
insulin-like growth factor-1 (rIGF-1) under conditions of substrate saturation in peripheral blood mononuclear
cells (PBMCs).
Methods: PBMCs from healthy male subjects were treated with either rhGH, at concentrations of 0.5, 5 and
50 μg/L, or rIGF-1 at concentrations of 100, 300 and 500 μg/L for 4 h. Mitochondrial membrane potential
(Δψm) and mitochondrial levels of highly reactive oxygen species (hROS) were subsequently analysed. This
analysis was performed by flow cytometry in digitonin permeabilized cells, following treatment with saturating
concentrations of various respiratory substrate combinations and the use of specific electron transport chain
(ETC.) complex inhibitors, enabling control over both the sites of electron entry into the ETC. at complexes I
and II and the entry of electrons from reduced carriers involved in β-oxidation at the level of ubiquinol.
Results: Neither rhGH nor rIGF-1 exerted any significant effect on Δψm or the rate of hROS production in
either lymphocyte or monocyte sub-populations under any of the respiratory conditions analysed.
Conclusion: That neither hormone was capable of attenuating levels of oxidative stress mediated via either
complex I linked respiration or lipid-derived respiration could have serious health implications for the use of
rhGH in healthy individuals, which is frequently associated with significant increases in the bioavailability of
free fatty acids (FFA). Such elevated supplies of lipid-derived substrates to the mitochondria could lead to
oxidative damage which would negatively impact mitochondrial function.
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Background
The electron transport chain (ETC.) is the principal site
of intracellular reactive oxygen species (ROS) produc-
tion, with 1–3 % of electrons transferred to O2 in a sin-
gle reduction reaction creating superoxide (O2
−) under
normal physiological conditions [1–3]. This in turn
leads to the formation of hydrogen peroxide (H2O2)
through the actions of superoxide dismutase [4].
Hyper-polarisation of mitochondrial membrane poten-
tial (Δψm) or inhibition of electron flow through the
ETC. leads to a prolonged reduction of core electron
transferring components within the enzyme complexes,
resulting in an increased rate of O2
− production [3].
It is widely recognised that O2
− production is derived
from electron ‘leakage’ from both NADH dehydrogen-
ase (Complex I) and cytochrome c-oxidoreductase
(Complex III) [5]. However, studies attempting to
identify the site at which the highest rates of O2
− are
generated have yielded conflicting results [5, 6]. Add-
itionally, enzymes involved in the transfer of electrons
during β-oxidation, such as electron transfer flavopro-
tein (ETF) and electron transfer flavoprotein quinine
oxidoreductase (ETF-QO), have also been identified as po-
tential sources of O2
− generation within the ETC. [6].
Accumulation of O2
− and H2O2, beyond the capacity
of the cell’s antioxidant defences to neutralize these
molecules, results in the generation of highly reactive
and short lived intermediates, such as peroxynitrate
(ONOO-) and hydroxyl radical [OH(•)] [1, 7]. These in-
termediates, termed “highly reactive oxygen species”
(hROS), are generated by the reaction of O2
− with nitric
oxide (NO) and of H2O2 with ferrous iron (Fe
2+) re-
spectively. While direct tissue damage has only been
attributed to O2
− and H2O2 when present at supra-
physiological concentrations, oxidative stress associated
with the presence of OH(•) is well established, owing to
its high non-specific reactivity with a variety of biomole-
cules [8]. In addition, whereas O2
− and H2O2 are neu-
tralized through the activity of antioxidant enzymes,
there are no known antioxidant defences responsible for
the removal of hROS [8]. The subsequent oxidative
damage to intracellular proteins, lipids and nucleic acids
caused by hROS is implicated in the process of aging
and associated with the development of several patho-
logical conditions including atherosclerosis, hyperten-
sion, cancer, diabetes and Parkinson’s disease [2, 9, 10].
A decline in the systemic release of growth hormone
(GH) and its subsequent stimulation of insulin-like
growth factor-1 (IGF-1) production is a well-known ef-
fect of aging in both humans and experimental animals
[4, 11]. Indeed, it has been demonstrated that, at circu-
lating concentrations of approximately 5–10 μg/L, these
hormones play an important role in modifying intracel-
lular levels of oxidative stress [12–14]. Csiszar et al. [4]
found that incubation of human coronary arterial endo-
thelial cells (HCAECs) for 24 h in the presence of
recombinant IGF-1 (rIGF-1) (10–1000 μg/L) and recom-
binant human growth hormone (rhGH) (333–3333 μg/L)
significantly reduced the mitochondrial production of
O2
− as well as overall O2
− and H2O2 cellular concen-
tration levels. Of note, previous research from our la-
boratory has demonstrated that four hours in the
presence of rhGH, at physiological concentrations (5–
10 μg/L), was enough to significantly reduce produc-
tion rates of mitochondrial O2
− molecules in periph-
eral blood mononuclear cells (PBMCs) [15]. Several
authors have also noted that GH is physically capable of
translocating to mitochondria [16, 17]. Ardail et al. [17]
observed that, in isolated mitochondria, succinate de-
hydrogenase (SDH) (Complex II) and cytochrome c oxi-
dase (COX) (Complex IV) exhibited decreased levels of
activity in the presence of high concentrations of rhGH
(2200 μg/L). This would indicate that the hormone can
attenuate mitochondrial O2
− generation via direct modu-
lation of the Δψm.
Despite the documented antioxidant effects resulting
from these hormones, at supra-physiological concen-
trations in-vivo GH is associated with adverse effects
leading to negative implications for normal physio-
logical functions [18, 19]. Patients with acromegaly, a
pathological disorder associated with a hyper-secretion of
GH from pituitary adenomas, suffer from a plethora
of complications involving neurological, cardiovascu-
lar, respiratory and metabolic processes. This condi-
tion leads to increased mortality of these patients if
GH and IGF-1 concentrations are not controlled and
reduced to normal levels [20]. Interestingly, the preva-
lence of diabetes in acromegalic patients ranges be-
tween 20 and 46 %. Additionally, in several studies
the inducement of supra-physiological GH concentra-
tions in healthy subjects has been linked to the devel-
opment of insulin resistance [18–20]. This is of
significance since increased levels of oxidative stress
have been demonstrated to directly induce insulin re-
sistance, while it is also widely cited as a causative
factor in the development of diabetes [19, 21]. This
suggests that the antioxidative capacities provided to
cells by GH and IGF-1, as observed in some studies
in-vitro, is negated at supra-physiological hormonal
concentrations in-vivo. Studies in animals lend sup-
port to this hypothesis, with transgenic mice manipu-
lated to over-express GH being found to have
increased levels of oxidative damage to liver proteins
and a suppressed antioxidant capacity when compared
to wild type mice [22].
While current studies examining the effect of rhGH
and rIGF-1 on cellular oxidative status have analysed
levels of O2
− and H2O2 production [4, 12, 13], to date
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no study has looked at how these hormones affect levels
of hROS such as OH(•) and ONOO-. Additionally, it is
not known how physiological concentrations of these
hormones influence the rate of free radical production
from the principal sites of electron ‘leak’ along the ETC.
or whether these rates differ at supra-physiological con-
centrations. In light of these points, the present study
aimed to i) evaluate mitochondrial levels of hROS and
ii) identify the principal complexes involved in ROS pro-
duction originating from the ETC. In line with previous
findings [15] we hypothesize that under the respiratory
conditions analysed rhGH and rIGF-1 will regulate oxi-
dative phosphorylation in order to meet the energy de-
mands associated with their metabolic effects. We
propose that this will be associated with an efficient
coupling of energy production at physiological concen-
trations leading to anti-oxidative effects, while at supra-
physiological concentrations a decreased efficiency of
electron transport will lead to an augmented production
of hROS. This study used PBMCs following incubation
with either rhGH or rIGF-1 at physiological and supra-
physiological concentrations. PBMCs, which consist of
lymphocyte and monocyte cell sub-populations, are eas-
ily isolated from whole blood, exhibit both GH and
IGF-1 cell surface receptors [23, 24] and have previ-
ously been demonstrated to incur changes in gene
and protein expression in response to rhGH and
rIGF-1 [25, 26]. Flow cytometric analysis was per-
formed simultaneously to assess hROS levels and
Δψm in digitonin permeabilized cells. This was carried
out following treatment with saturating concentrations
of various respiratory substrate combinations and in
the presence of specific ETC. complex inhibitors, en-
abling control over the sites of electron entry into the
ETC. at complexes I and II, but also over the entry
of electrons from reduced carriers involved in β-
oxidation at the level of ubiquinol.
Methods
Subjects
Ten healthy male subjects (mean ± SEM: age = 23 ± 1 year,
height = 1.78 ± .02 m, body mass = 77.1 ± 1.9 kg, BMI =
24.39 ± .71 kg/m2) were recruited to participate in the study
which was approved by the Bond University Human
Research Ethics Committee (BUHREC-RO1134). All
subjects were given information on the nature of the
study and the associated risks involved. These were
explained to them prior to providing written informed
consent. Exclusion criteria included smoking, the use
of therapeutic, recreational or performance enhancing
drugs, including anabolic steroids and rhGH up to
twelve months prior to participation in the study, a
history of diabetes, cardiovascular associated disease
or the use of prescription medications.
Reagents used
Hanks balanced salt solution (HBSS), RPMI Medium
1640, carbonyl cyanide m-chlorophenylhydrazone
(CCCP), 1,1′,3,3,3′,3′-hexamethylindodicarbo-cyanine iod-
ide (DilC1(5)), 3′-p-hydroxyphenyl fluorescein (HPF),
and sodium pyruvate were purchased from Invitrogen
(Carlsbad, CA, USA). L-malic acid (malate – pH ad-
justed to 7.4), sodium succinate, sodium octanoate,
ammonium iron (II) sulphate, H2O2, rotenone, digitonin,
sucrose, potassium phosphate monobasic (KH2PO4), mag-
nesium chloride (MgCl2), potassium morpholinopropane
sulphonate (MOPS), adenosine diphosphate (ADP), ethyl-
enediaminetetraacetic acid (EDTA) and bovine serum
albumin (BSA) were purchased from Sigma Aldrich (St
Louis, MO, USA). Phosphate buffered saline (PBS) was
purchased from Kinetic (Burpengary, QLD, Australia).
Ficoll-Paque PLUS was obtained from GE Healthcare
(Rydalmere, NSW, Australia). Finally, rhGH was pur-
chased from Pfizer (Sydney, NSW, Australia) and rIGF-1
was purchased from Biocore (Sydney, NSW, Australia).
Blood sample collection and PBMC isolation
Following an overnight fast, subjects underwent a blood
sample collection, with the insertion of a catheter into
an antecubital vein drawing 24 mL of blood into four
6 mL lithium heparinised Vacutainers (BD, CA, USA).
Collected blood was diluted in an equal volume of sterile
PBS and subsequently layered over Ficoll-Paque PLUS at
a ratio of 2:1. All samples were centrifuged at 450*g for
30 mins for the separation of PBMCs from whole blood.
Isolated cells were washed in HBSS and their concentra-
tion was determined using a Countess automated cell
counter (Invitrogen, Carlsbad, CA, USA). Finally, cells
were resuspended in RPMI 1640 cell culture medium at
a concentration of 1*106-cells/mL.
GH and IGF-1 treatment
Isolated PBMCs were divided into aliquots for subse-
quent experimentation with cells either remaining un-
treated or administered rhGH (at concentrations of 0.5,
5 or 50 μg/L) or rIGF-1 (at concentrations of 100, 300
or 500 μg/L). All cell samples were subsequently incu-
bated for 4 h at 37 °C and in the presence of 5 % CO2.
Treatment with respiratory substrates and inhibitors
Following the experimental procedures and treatments,
plasma membranes of these cells were permeabilized for
the analysis of Δψm and hROS generation under differ-
ing respiratory conditions, a method adapted from the
work of Pham et al. [27]. Sample cell aliquots were
treated with digitonin at a concentration of 5 μg/mL for
5 mins, washed in PBS and resuspended in a respiratory
buffer (0.25 M sucrose, 2 mM KH2PO4, 5 mM MgCl2,
1 mM EDTA, 0.1 % BSA, 1 mM ADP and 20 mM
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MOPS – pH adjusted to 7.4). The subsequent adminis-
tration choice of substrate combinations with these cells
gives rise to understanding either complex I, complex II
or fatty acid mediated respiration.
Administration of the combination of pyruvate
(5 mM) and malate (5 mM) (Pyr/Mal) activates isocitrate
dehydrogenase, α-ketoglutarate dehydrogenase complex
and malate dehydrogenase, which reduce NAD+ leading
to the initiation of complex I mediated respiration.
Complex II is not involved under these respiratory con-
ditions, as malate equilibrates with fumarate at concen-
trations above 2 mM, inhibiting the conversion of
succinate to fumarate and preventing the formation of
FADH2 [28].
Administration of succinate (10 mM), in the presence
of rotenone (20 μM) (Succ/Rot), activates SDH, which
reduces FAD leading to the initiation of complex II me-
diated respiration. Rotenone acts to inhibit the flow of
electrons through complex I and to prevent accumula-
tion of oxaloacetate, a potent inhibitor of SDH [28].
Rotenone is also necessary to prevent reverse electron
transfer to complex I, which stimulates the production
of ROS [28].
Administration of the medium chain fatty acid octano-
ate (10 mM) and malate (2 mM) (Oct/Mal) mediate the
transfer of electrons to reducing equivalents via β-
oxidation. The use of octanoate, the oxidation of which
is not carnitine dependent, to assess respiratory activity
in isolated mitochondria has been previously demon-
strated [29]. Additionally, malate at these concentrations
acts as a “sparker” as it is known to significantly increase
the rate of β-oxidation [28, 30].
Analysis of variables
Mitochondrial ΔΨ was analysed by flow cytometry using
the lipophilic cationic dye, DilC1(5). The dye accumu-
lates in the mitochondria as a function of membrane po-
tential at concentrations below 100nM and fluoresces at
an emission maximum of 658 nm when excited at
633 nm [31]. The generation of hROS was analysed by
flow cytometry using the fluorescein derivative, HPF.
HPF is a highly selective ROS indicator, only emitting a
fluorescent signal upon reacting with either OH(•) or
ONOO- [7]. The probe fluoresces at an emission max-
imum of 515 nm when excited at 488 nm.
Negative control samples for Δψm were incubated at
37 °C in 5 % CO2 for 5 min in the presence of 50 μM of
CCCP in order to dissipate Δψm. Positive control sam-
ples for hROS were incubated at 37 °C in 5 % CO2 for
5 min in the presence of 100 μM ammonium iron (II)
sulphate and 1 mM H2O2 to induce OH(•) generation
via the Fenton reaction.
Aliquots from each treatment condition (1 mL) were
subsequently incubated at 37 °C in 5 % CO2 for 15 min
in the presence of DilC1(5) at a concentration of 10nM
and HPF at a concentration of 10 μM. Following in-
cubation, all samples were washed and resuspended
in 500 μL PBS, prior to immediate analysis by flow
cytometry.
Analysis by flow cytometry
All samples were analysed using a FACS Calibur flow
cytometer (BD, Australia). For the analysis of Δψm, sam-
ples were excited at a wavelength of 633 nm with fluor-
escent emissions detected in channels using a bandpass
filter with a range of ≥650 nm. For the analysis of hROS
production, samples were excited at a wavelength of
488 nm with fluorescent emissions detected in channels
using a bandpass filter with a range of 515-545 nm. For
all samples analysed, a total of 10,000 events were col-
lected while lymphocyte and monocyte populations were
gated and analysed separately. All data collected was
analysed using Cellquest Pro software (BD, Australia).
Statistical analysis
A factorial multivariate analysis of variance (MANOVA)
was used to determine whether significant interactions
existed between respiratory conditions and hormonal
treatments for each of the analysed variables, while
Bonferroni’s multiple comparisons were used for post
hoc analysis between individual treatment conditions
(SPSS Inc, PAWS Statistics Version 18, USA). Statistical
significance was determined at an alpha level of 0.05.
Results
Mitochondrial membrane potential
Treatment with CCCP significantly reduced DilC1(5)
mean channel fluorescence (AU) from samples in the
presence of Pyr/Mal (mean difference ± SEM, 95 % confi-
dence intervals, p-values: −130 ± 9 AU, −149 to -110 AU,
P ≤ 0.05), Succ/Rot (−182 ± 19 AU, −225 to -139 AU,
P ≤ 0.05) and Oct/Mal (−163 ± 19 AU, −205 to −120 AU,
P ≤ 0.05) compared to untreated samples under the same
respiratory conditions in the lymphocyte sub-population.
Fluorescence values from Succ/Rot treated samples were
significantly higher compared to Pyr/Mal (120 ± 9 AU, 96
to 144 AU, P ≤ 0.05) and Oct/Mal (55 ± 9 AU, 31 to
79 AU, P ≤ 0.05) treated samples. In addition, Oct/Mal
treated samples were significantly higher compared to
Pyr/Mal (65 ± 9 AU, 41 to 89 AU, P ≤ 0.05) treated sam-
ples (Fig. 1a).
In the monocyte sub-population treatment with
CCCP also significantly reduced DilC1(5) mean channel
fluorescence from samples in the presence of Pyr/Mal
(−854 ± 67 AU, −1007 to −702 AU, P ≤ 0.05), Succ/Rot
(−925 ± 56 AU, −1056 to −794 AU, P ≤ 0.05) and Oct/Mal
(−930 ± 60 AU, −1067 to −794 AU, P ≤ 0.05) compared to
untreated samples under the same respiratory conditions.
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Fluorescence values from Succ/Rot treated samples were
significantly higher compared to Pyr/Mal (146 ± 28 AU,
70 to 222 AU, P ≤ 0.05) treated samples but were not
significantly different from Oct/Mal treated samples
(44 ± 28 AU, −31 to 120 AU, P = 0.73). Oct/Mal
treated samples were also significantly higher in fluor-
escence compared to Pyr/Mal (102 ± 28 AU, 26 to
178 AU, P ≤ 0.05) treated samples (Fig. 1b).
Neither GH (Fig. 2) nor IGF-1 (Fig. 3) exerted any
significant effect on Δψm as indicated by DilC1(5)
mean channel fluorescence values in either lympho-
cyte (P = 0.97) or monocyte (P = 0.75) sub-populations
at any concentration administered. Finally, no signifi-
cant interaction effect between hormonal treatment
and respiratory substrate condition was observed in
either lymphocyte (P = 0.99) or monocyte (P = 0.99)
sub- populations.
Highly reactive oxygen species production
Following treatment with H2O2 and ammonium iron (II)
sulphate, HPF mean channel fluorescence values (AU)
were significantly higher from samples in the presence
of Pyr/Mal (mean difference ± SEM, 95 % confidence in-
tervals, p-values: 102 ± 21 AU, 55 to 149 AU, P ≤ 0.05),
Succ/Rot (27 ± 2 AU, 22 to 32 AU, P ≤ 0.05) and Oct/
Mal (46 ± 5 AU, 33 to 58 AU, P ≤ 0.05) compared to
untreated samples under the same respiratory conditions
in the lymphocyte sub-population. Fluorescence values
from Pyr/Mal treated samples were significantly higher
compared to Succ/Rot (56 ± 1 AU, 53 to 58 AU, P ≤ 0.05)
and Oct/Mal (45 ± 1 AU, 42 to 48 AU, P ≤ 0.05) treated
samples. In addition, fluorescence values from Oct/Mal
treated samples were significantly increased compared to
Succ/Rot samples (10 ± 1 AU, 8 to 13 AU, P ≤ 0.05)
(Fig. 4a).
In the monocyte sub-population treatment with H2O2
and ammonium iron (II) sulphate also significantly
increased HPF mean channel fluorescence (AU) from
Fig. 1 Mitochondrial Membrane Potential a) DilC1(5) Mean Channel
Fluorescence from lymphocytes for negative control samples treated
with CCCP compared to untreated samples under different substrate
conditions. (a – P < 0.05 compared to untreated; b – P < 0.05
compared to Succ/Rot; c – P < 0.05 compared to Oct/Mal; d – P < 0.05
compared to Pyr/Mal). b) DilC1(5) Mean Channel Fluorescence from
monocytes for negative control samples treated with CCCP compared
to untreated samples under different substrate conditions. (a – P < 0.05
compared to untreated; b – P < 0.05 compared to Succ/Rot; c –
P < 0.05 compared to Oct/Mal; d – P < 0.05 compared to Pyr/Mal)
Fig. 2 Mitochondrial Membrane Potential a DilC1(5) Mean Channel
Fluorescence from lymphocytes for growth hormone treated
samples compared to untreated samples under different substrate
conditions. b DilC1(5) Mean Channel Fluorescence from monocytes
for growth hormone treated samples compared to untreated
samples under different substrate conditions
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samples in the presence of Pyr/Mal (1578 ± 237 AU,
1042 to 2115 AU, P ≤ 0.05), Succ/Rot (2308 ± 246 AU,
1752 to 2864 AU, P ≤ 0.05) and Oct/Mal (2458 ± 137 AU,
2148 to 2769 AU, P ≤ 0.05) compared to untreated sam-
ples under the same respiratory conditions. Fluorescence
values from Pyr/Mal treated samples were significantly in-
creased compared to Succ/Rot (377 ± 6 AU, 360 to
393 AU, P ≤ 0.05) and Oct/Mal (341 ± 6 AU, 324 to
357 AU, P ≤ 0.05) treated samples. In addition, fluores-
cence values from Oct/Mal treated samples were sig-
nificantly increased compared to Succ/Rot samples
(36 ± 6 AU, 19 to 53 AU, P ≤ 0.05) (Fig. 4b).
Neither GH (Fig. 5) nor IGF-1 (Fig. 6) exerted any
significant effect on hROS levels as indicated by HPF
mean channel fluorescence values in either lympho-
cyte (P = 0.90) or monocyte (P = 0.85) sub-populations
at any concentration administered. Finally, no signifi-
cant interaction effect between hormonal treatment
and respiratory substrate condition was observed in
either lymphocyte (P = 0.99) or monocyte (P = 0.39)
sub-populations.
Discussion
The principal finding of this study was that neither
rhGH nor rIGF-1 exerted any significant effect on the
rate of production of the highly reactive oxidants, OH(•)
and ONOO-, under the respiratory conditions analysed,
at any administered hormonal concentration. While this
is the first study to examine the effects of rhGH/rIGF-1
on the production of these molecules, other studies have
found that, in-vitro, these hormones exhibit significant
effects on the generation of the reactive intermediates
O2
− and H2O2, molecules whose creation precedes that
of hROS [4, 32, 33]. Csiszar et al. [4] found that both
mitochondrial and cellular levels of O2
− were signifi-
cantly reduced in HCAECs following treatment at both
physiological and supra-physiological concentrations of
rhGH (333–3333 μg/L) and rIGF-1 (10–1000 μg/L).
Fig. 3 Mitochondrial Membrane Potential a DilC1(5) Mean Channel
Fluorescence from lymphocytes for IGF-1 treated samples compared
to untreated samples under different substrate conditions. b DilC1(5)
Mean Channel Fluorescence from monocytes for IGF-1 treated samples
compared to untreated samples under different substrate conditions
Fig. 4 Highly Reactive Oxygen Species Production a) HPF Mean
Channel Fluorescence from lymphocytes for positive control samples
treated with H2O2 and ammonium iron (II) sulphate compared to
untreated samples under different substrate conditions. (a – P < 0.05
compared to untreated; b – P < 0.05 compared to Succ/Rot;
c – P < 0.05 compared to Oct/Mal; d – P < 0.05 compared to Pyr/
Mal). b) HPF Mean Channel Fluorescence from monocytes for
positive control samples treated with H2O2 and ammonium iron (II)
sulphate compared to untreated samples under different substrate
conditions. a – P < 0.05 compared to untreated; b – P < 0.05 compared
to Succ/Rot; c – P < 0.05 compared to Oct/Mal; d – P < 0.05 compared
to Pyr/Mal)
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Using the non-specific ROS probe 2′,7′-dichlorodihy-
drofluorescein diacetate (H2DCFDA), Thum et al. [32]
also demonstrated significantly decreased intracellular
ROS levels in cultured human endothelial cells 24 h post
treatment with rhGH at concentrations of 100 and
1000 μg/L. In contrast, Gustafsson et al. [33] found that
no significant change in intracellular ROS levels was
induced by the presence of rIGF-1 (75 μg/L) in cul-
tured human neuroblastoma cells under standard sub-
strate conditions. However, rIGF-1 was effective in
preventing the rise of hyperglycaemic-induced ROS
production in these cells at glucose concentrations in
the range of 30–60 mM. Csiszar et al. [4] related the
antioxidant effects of rhGH/rIGF-1 directly to the up-
regulated expression of the mitochondrial matrix anti-
oxidant enzymes manganese-superoxide dismutase
(Mn-SOD) and glutathione peroxidase-1 (GPX-1), as
well as the inter membrane copper, zinc-superoxide
dismutase (Cu, Zn-SOD). However, Gustafsson et al.
[33] reported significant increases in uncoupling pro-
tein 3 (UCP3) expression following rIGF-1 treatment.
The authors attributed the hormone anti-oxidative ef-
fects directly to a decrease in the rate of respiratory
chain electron loss as a result of an uncoupling
phenomenon of oxidative phosphorylation under sat-
urating substrate conditions.
Of note, the anti-oxidative effects reported in previous
in-vitro studies of rhGH and rIGF-1 are the result of a
24–72 h treatment period [4, 32, 33]. In contrast, our
study was undertaken over a shorter period of four
hours. It is plausible that the antioxidant effects of these
hormones are time dependant and that four hours is in-
sufficient for their manifestation. Despite this, our la-
boratory has previously demonstrated that human
lymphocytes treated with rhGH in-vitro, at physiological
concentrations (5–10 μg/L), significantly decreased
levels of mitochondrial derived O2
− following only four
hours of incubation. In addition, Thum et al. [32] also
observed significant decreases in intracellular ROS
Fig. 5 Highly Reactive Oxygen Species Production a HPF Mean
Channel Fluorescence from lymphocytes for growth hormone
treated samples compared to untreated samples under different
substrate conditions. b HPF Mean Channel Fluorescence from
monocytes for growth hormone treated samples compared to
untreated samples under different substrate conditions
Fig. 6 Highly Reactive Oxygen Species Production a HPF Mean
Channel Fluorescence from lymphocytes for IGF-1 treated samples
compared to untreated samples under different substrate conditions.
b HPF Mean Channel Fluorescence from monocytes for IGF-1
treated samples compared to untreated samples under different
substrate conditions
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production in human endothelial cells following GH ad-
ministration after four hours, which was attributed to an
improved regulation of cellular metabolic and antioxi-
dant status. This suggests that rhGH exerts its effects on
the rate of mitochondrial ROS generation via direct
regulation of the organelle at the level of electron trans-
fer within the ETC. [15]. In support of this assertion, it
has previously been demonstrated that GH mediates
intracellular signals that directly modulate the activity of
the ETC. [17]. In the present study, neither rhGH nor
rIGF-1 exerted a significant effect on Δψm under the re-
spiratory conditions analysed at any administrated hor-
monal concentration. The finding that neither hormone
induced a change in the rate of hROS production is pos-
sibly due to the effect exerted on Δψm by saturating
concentrations of respiratory substrates. In addition, sat-
urating concentrations of ADP were also utilized in the
study in order to initiate state 3 (phosphorylating) res-
piration following cellular permeabilization, which
doesn’t accurately reflect endogenous respiration in-vivo
where cells cycle between state 3 and state 4 (non-
phosphorylating) respiration [34]. Thus, any subtle ef-
fects induced by rhGH or rIGF-1 on the efficiency of
oxidative phosphorylation may have been negated
under the respiratory conditions analysed. Whether
treatment with rhGH/rIGF-1 over longer periods (24–
72 h) would exert any effect under these respiratory
conditions remains undetermined and should be the
target of future studies.
Sanz et al. [35] found that two weeks of GH treatment
in Wistar rats resulted in significant increases in the
levels of oxidative damage to mitochondrial DNA des-
pite observed decreases in the rate of H2O2 generation,
indicating that initial pro-oxidative effects preceded any
changes in antioxidant capacity induced by the hormone.
Together with the finding by Gustafsson et al. [33] that
rIGF-1 only influenced the rate of ROS production in
human neuroblastoma cells in-vitro following the
addition of a stimulus to induce oxidative stress, this
suggests that the changes induced by GH/IGF-1 on cel-
lular antioxidant capacity are not mediated via a direct
up-regulation of the expression of antioxidant enzymes.
Indeed, it has been suggested that the influence exerted
by the GH/IGF-1 axis on cellular oxidative capacity is
mediated via the mechanism of mitochondrial hormesis,
an adaptive response to small sub-lethal increases in
mitochondrial derived ROS concentrations, which
subsequently act as signalling molecules leading to an
up-regulation of antioxidant enzymes and increased
resistance to oxidative stress [12, 36]. In addition,
there is growing evidence to suggest that Sirtuins or
Sir2 (silent information regulator 2)-related enzymes
(SIRT1–SIRT7) may mediate this response in relation
to GH/IGF-1 [37]. The presence of oxidative insult
has been found to significantly increase the expres-
sion of SIRT1, which is known to act via a deacetyla-
tion of the forkhead box O (FoxO) transcription
factor to exert changes in the expression of numerous
proteins that regulate mitochondrial metabolism and
antioxidant capacity, among which is an up-regulation
of the antioxidant enzymes, Mn-SOD and GPX-1
[12]. GH deficient Lewis Dwarf rats exhibit a signifi-
cant down-regulation of SIRT1, which was found to
be reversed following repletion of physiological GH
concentrations [12]. SIRT4 is an ADP-ribosyltransferase
which serves as a negative regulator of mitochondrial oxi-
dative capacity [38]. The expression of SIRT4 is found to
be down-regulated in obese subjects, likely in response to
oxidative stress arising from greater concentrations of
FFA availability [38]. In addition, a low GH/IGF-1 status
was also found to be associated with a significant decrease
in circulating levels of SIRT4 [39]. Such a response is
mediated in an attempt to increase FFA oxidative
capacity and subsequently reduce mitochondrial ROS
production [38].
It is likely that modulation of oxidative phosphoryl-
ation by the GH/IGF-1 axis is not the only factor affect-
ing the efficiency of electron transfer in-vivo. Other
factors which induce oxidative stress by up-regulating
the rate of mitochondrial ROS production likely contrib-
ute to an interactive effect on mitochondrial respiration
which is necessary for the production of ROS at concen-
trations that will maximize their effect as intracellular
messengers to induce an antioxidant response. Hence, a
pre-existing pro-oxidative status within the cell may be
necessary for GH/IGF-1 to induce any significant
changes in antioxidant capacity, possibly explaining the
absence of any significant effect on hROS levels, follow-
ing pre-treatment with rhGH and rIGF-1 in-vitro in the
present study.
In animal studies, cellular oxidative responses to rhGH
and rIGF-1 administration have varied depending on the
cell type analysed, indicating that any antioxidant effects
of the GH/IGF-1 pathway are tissue specific [4, 35, 40].
In contrast to the findings of Csiszar et al. [4], who
showed that in-vitro rhGH and rIGF-1 treatment in car-
diomyocytes isolated from wild type mice significantly
up-regulated the expression of Mn-SOD, Cu, Zn-SOD
and GPX-1, Brown-Berg et al. [40] observed significant
decreases in the expression of Mn-SOD, GPX-1 and
catalase following similar treatment in murine hepato-
cytes. Furthermore, Sanz et al. [35] observed signifi-
cant increases in oxidative damage to liver tissue
isolated from Wistar rats following two weeks of GH
treatment, while oxidative damage was significantly
decreased in isolated cardiac tissue from the same an-
imals. Discrepancies in the GH/IGF-1 effects between
tissue types could be attributed to the expression of
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cell specific isoforms of GH and IGF-1 regulated lo-
cally at a tissue level [4]. Indeed, several tissue types
have been shown to be capable of locally producing
both GH and IGF-1, including sub-populations of hu-
man mononuclear leukocytes [41–43]. Thus, the auto-
crine/paracrine activation of GH/IGF-1 pathways may be
more relevant to the hormonal effect on the rate of mito-
chondrial ROS production in these cell types, than local
concentrations of the systemic isoforms secreted from the
anterior pituitary and the liver, respectively [4]. In support
of this, Vinciguerra et al. [44] showed that the “local
muscle specific” IGF-1 isoform (mIGF-1) in murine cardi-
omyocytes elicited a protective effect in response to para-
quat induced oxidative stress, while increasing
concentrations of the systemic IGF-1 isoform itself elicited
a pro-oxidative response. The mIGF-1 isoform contains a
class 1 signalling peptide sequence on its N-terminal
which is 48 amino acids in length and a C-terminal
“Ea extension” peptide sequence containing 35 amino
acids, which the mature systemic IGF-1 isoform does
not possess [44–46]. Both isoforms are known to trig-
ger phosphorylation of the IGF-1 receptor [44]. How-
ever, the systemic isoform is found to typically
activate phosphoinositide 3-kinase/protein kinase B
(PI3K/Akt) and mitogen-activated protein kinase
(MAPK) dependent pathways, while mIGF-1 has been
shown to instead activate 3-phosphoinositide-dependent
kinase (PDK1) and serum- and glucocorticoid-inducible
kinase-1 (SGK1) signalling molecules in cardiomyocytes,
demonstrating differences in the isoforms respective sig-
nalling mechanisms downstream of surface receptor acti-
vation [44]. Hence, the activation of autocrine/paracrine
pathways by locally produced isoforms may be required
for significant effects on antioxidant capacity to be exhib-
ited in the cell populations analysed here. For this reason,
the investigation of how rhGH and rIGF-1 effect mito-
chondrial hROS production in other cell types, such as
endothelial cells, should be the target of future studies.
The present study also found the level of mitochon-
drial hROS production to be significantly increased
under conditions supporting NADH-linked respiration
in comparison to all other respiratory conditions ana-
lysed, indicating that electron leakage at the site of com-
plex I is an important contributor to the level of ROS
production within the mitochondrial matrix. Such find-
ings are in agreement with studies which have previously
evaluated the rate of ROS production in isolated mito-
chondria [9, 47–49]. In contrast, under conditions of
complex II linked respiration, hROS levels were signifi-
cantly decreased in comparison to other respiratory con-
ditions, indicating that complexes II – IV of the ETC. do
not significantly contribute to electron leak on the
matrix side of the inner mitochondrial matrix. Whether
cytosolic levels of hROS were affected by electron leak
initiated at complex III could not be determined in the
present study due to the probable diffusion of such mol-
ecules out of the cell following surface membrane
permeabilization.
In addition, mitochondrial hROS production was sig-
nificantly increased in the presence of octanoate in com-
parison to complex II linked respiration, indicating that
reducing equivalents derived from β-oxidation play a
role in the generation of hROS. It must be noted that β-
oxidation generates equal amount of NADH, transfer-
ring electrons to complex I, and FADH2 transferring
electrons to ubiquinones on the inner mitochondrial
membrane via ETF and ETF–QO [6]. Thus, the princi-
pal site of electron leak under conditions of fatty acid
oxidation is yet to be determined. While rates of mito-
chondrial ROS production under conditions of lipid-
derived respiration did not reach the high values ob-
served under conditions of complex I linked respiration
in the present study, St-Pierre et al. [6] demonstrated
significant elevations in O2
− levels in isolated mitochon-
dria from rat skeletal muscle and cardiac tissue when re-
spiring on palmitoyl carnitine. The authors attributed
this to a prolonged reduction of ETF and ETF-QO, in
addition to an increase in complex I mediated electron
leakage. Indeed, elevated concentrations of long-chain
fatty acids in-vivo, in excess of the mitochondrial cap-
acity to oxidize them, are known to become trapped in
the mitochondrial matrix, elevating the redox state of
the organelle and giving rise to the formation of highly
reactive lipid peroxides [50]. Thus, long-chain fatty
acids, which require active transportation across the
inner mitochondrial matrix, may be more prone to indu-
cing ROS production than the medium-chain fatty acids
utilised in the present study, molecules that can enter
and leave the mitochondrial matrix freely [51].
Conclusions
In conclusion, it is worth noting that high hROS values
were recorded under saturated conditions of both com-
plex I mediated and lipid-derived respiration which nei-
ther rhGH or rIGF-1 were capable of attenuating at the
diverse hormonal concentrations tested. This could have
direct implications for the administration of these hor-
mones in-vivo. Indeed, GH has been demonstrated to in-
duce substantial elevations in serum FFA availability in
healthy subjects [18, 52, 53], while both GH and IGF-1
are known to increase lipid derived oxidation in-vivo
[18]. Such elevated supplies of lipid-derived substrates to
the mitochondria could lead to oxidative damage which
would negatively impact mitochondrial function, espe-
cially with long chain FA [54]. Different levels of fatty
acid intake in subjects administered with GH or IGF-1
might also have health implications and further studies
may be warranted to record diet related habits.
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